Non-Interventional Retrospective Correlation Of Tumor Mutational Status To Clinical Benefit Of GIST Patients Treated With Sunitinib
NCT ID: NCT01459757
Last Updated: 2013-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
322 participants
OBSERVATIONAL
2011-10-31
2013-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST)
NCT00457743
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
NCT01396148
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
NCT02164240
Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
NCT01308034
A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors
NCT01731925
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Data generated from the past sunitinib A6181036 GIST study
non-interventional
Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
non-interventional
Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Washington Hospital Center
Washington D.C., District of Columbia, United States
Davis Cancer Pavilion and Shands Medical Plaza
Gainesville, Florida, United States
Shands Cancer Hospital at the University of Florida
Gainesville, Florida, United States
Shands Hospital at the University of Florida
Gainesville, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Masonic Cancer Center - Clinical Trials Office
Minneapolis, Minnesota, United States
Oregon Health and Science University
Portland, Oregon, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
University of Washington
Seattle, Washington, United States
Prince of Wales Hospital, Oncology Day Center
Randwick, New South Wales, Australia
Ashford Cancer Centre Research
Kurralta Park, South Australia, Australia
Peter MacCallum Cancer Institute, Department of Medical Oncology
East Melbourne, Victoria, Australia
UZ Leuven
Leuven, , Belgium
Hopital Notre-dame du Centre Hospitalier Universitaire de Montreal
Montreal, Quebec, Canada
Herlev Hospital
Herlev, , Denmark
Helsingin yliopistollinen keskussairaala/Syopatautien klinikka
Helsinki, , Finland
Institut Bergonie
Bordeaux, France, France
CHU La Timone, Service d'Oncologie Medicale
Marseille, France, France
Centre L� B�rd
Lyon, Lyon Cedex, France
HELIOS Klinikum Berlin-Buch, Klinik fuer Interdisziplinaere Onkologie
Berlin, , Germany
Klinikum der Universitaet zu Koeln
Cologne, , Germany
Schwerpunktpraxis fuer ambulante Tumortherapie
Düsseldorf, , Germany
Tata Memorial Centre
Mumbai, Maharashtra, India
Leids Universitair Medisch Centrum/ Klinische Oncologie
Leiden, Netherlands, Netherlands
Klinika Nowotworow Tkanek Miekkich i Kosci
Warsaw, Poland, Poland
Narodny Onkologicky ustav
Bratislava, , Slovakia
Seoul National University Hospital/Department of Internal Medicine
Seoul, , South Korea
Asan Medical Center, Department of Internal Medicine
Seoul, , South Korea
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Hospital Universitario Virgen Macarena
Seville, Sevilla, Spain
Centre Hospitalier Universitaire Vaudois
Lausanne, Lausanne, Switzerland
Sarcoma Unit
London, , United Kingdom
Christie Hospital NHS Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schoffski P, Schuette J, Soulieres D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC. Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016 Jan 15;16:22. doi: 10.1186/s12885-016-2051-5.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6181199
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.